National Institute for Health and Care Excellence. (2018) Nalmefene for reducing alcohol consumption in people with alcohol dependence. London: NICE. Technology appraisal guidance TA325.
Preview | Title | Contact |
---|---|---|
|
PDF (Nalmefene for reducing alcohol consumption in people with alcohol dependence)
237kB |
External website: https://www.nice.org.uk/guidance/ta325
Nalmefene is recommended within its marketing authorisation in the UK, as an option for reducing alcohol consumption, for people with alcohol dependence:
- who have a high drinking risk level (defined as alcohol consumption of more than 60 g per day for men and more than 40 g per day for women, according to the World Health Organization's drinking risk levels) without physical withdrawal symptoms and
- who do not require immediate detoxification. The marketing authorisation states that nalmefene should:
only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption and - be initiated only in patients who continue to have a high drinking risk level 2 weeks after initial assessment.
Item Type
Report
Publication Type
International, Guideline, Report
Drug Type
Alcohol
Intervention Type
Drug therapy, Treatment method
Date
2018
Identification #
Technology appraisal guidance TA325
Pages
49 p.
Publisher
NICE
Corporate Creators
National Institute for Health and Care Excellence
Place of Publication
London
Edition
Revised edition
EndNote
Subjects
B Substances > Alcohol
G Health and disease > Substance use disorder (addiction) > Alcohol use disorder > Alcohol dependence
HJ Treatment or recovery method > Substance disorder treatment method > Substance disorder drug therapy (pharmacological treatment)
J Health care, prevention, harm reduction and treatment > Treatment and maintenance > Treatment factors
VA Geographic area > Europe > United Kingdom
G Health and disease > Substance use disorder (addiction) > Alcohol use disorder > Alcohol dependence
HJ Treatment or recovery method > Substance disorder treatment method > Substance disorder drug therapy (pharmacological treatment)
J Health care, prevention, harm reduction and treatment > Treatment and maintenance > Treatment factors
VA Geographic area > Europe > United Kingdom
Repository Staff Only: item control page